Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-SA02 for Staphylococcus aureus bacteremia. These 10 stocks could mint the next wave of ...

New data shows Recce's topical gel is highly effective against two challenging antibiotic-resistant bacteria affecting burns.

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

The FDA has granted Fast Track and QIPD designations to CMTX-101 for the treatment of CF in patients affected by chronic bacterial pulmonary infections.

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On August 11, 2025, Armata Pharmaceuticals entered into a secured credit ...

Advancement of modular therapies offers a new dynamic for today’s patients, but there’s still a need to maintain infection ...

Contact lenses are preferred for convenience, but this should not compromise maintaining adequate precautions; otherwise, ...

A 56-year-old woman with a history of relapsed/refractory IgG kappa multiple myeloma presented with a 3-day history of right ...

A FRESH bombshell theory in Lucy Letby’s case is a “smoking gun” that casts even MORE doubt over the killer nurse’s convictions, medical experts say. After two ...

A senior nurse at Lucy Letby’s hospital warned she was facing her “worst nightmare” after deadly bacteria was found on ...

Synthetic parabens and formaldehyde releasers are falling out of favor, but keeping creams safe from microbes remains a ...